Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.

Tronieri JS, Wadden TA, Walsh O, Berkowitz RI, Alamuddin N, Gruber K, Leonard S, Bakizada ZM, Chao AM

International journal of obesity (2005)29 Mar 2019Cited by 55 (Europe PMC)

PMID30926955PMCIDPMC6766432DOI10.1038/s41366-019-0348-6PepBankPUB-30926955

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, no other differences in appetite ratings among any groups were found at week 52.
In plain wordsIn adults with obesity, appetite ratings did not differ among the groups at week 52.
Peptide
Liraglutide
Outcome
No significant changeAppetite ratings at week 52
Study
n = 113
Comparator
IBT alone, IBT-liraglutide and Multi-component groups
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 52 weeksAs given in this study (human).
Source sentences
Summary
There were no other differences among any groups at week 52.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695513
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, IBT with liraglutide produced a loss of 11.8% of baseline weight at week 52, compared with 6.2% with IBT alone.
In plain wordsIn adults with obesity, adding liraglutide to behavioral therapy gave more weight loss at one year than behavioral therapy alone.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at week 52
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg/day · 52 weeksAs given in this study (human).
Measurements
Weight loss at week 52
11.8 % baseline weight
IBT-liraglutide
Weight loss at week 52
6.2 % baseline weight
IBT-alone
Source sentences
Summary
At week 52, participants treated by IBT-alone lost 6.2 ± 1.6% of baseline weight, compared with 11.8 ± 1.6% and 12.1 ± 1.5% in the IBT-liraglutide and Multi-component groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695501
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, IBT with liraglutide reduced hunger at week 6 more than IBT alone.
In plain wordsIn adults with obesity, hunger fell more at week 6 with liraglutide plus behavioral therapy than with behavioral therapy alone.
Peptide
Liraglutide
Outcome
DecreaseHunger change at week 6
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 6 weeksAs given in this study (human).
Measurements
Hunger change at week 6
−16.8 mm
IBT-liraglutide
Hunger change at week 6
−0.3 mm
IBT-alone
Source sentences
Summary
Compared to IBT-alone, IBT-liraglutide participants reported larger reductions at week 6 in hunger (-0.3 ± 4.2 vs -16.8 ± 4.0 mm, p = .005
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695503
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity, IBT with liraglutide reduced food preoccupation at week 6 more than IBT alone.
In plain wordsIn adults with obesity, thinking about food fell more at week 6 with liraglutide plus behavioral therapy than with behavioral therapy alone.
Peptide
Liraglutide
Outcome
DecreaseFood preoccupation change at week 6
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 6 weeksAs given in this study (human).
Measurements
Food preoccupation change at week 6
−16.3 mm
IBT-liraglutide
Food preoccupation change at week 6
0.2 mm
IBT-alone
Source sentences
Summary
and food preoccupation (+0.2 ± 3.7 vs -16.3 ± 3.6 mm, p = .002
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695504
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity, IBT with liraglutide increased fullness after meals at week 6 more than IBT alone.
In plain wordsIn adults with obesity, feeling full after meals rose more at week 6 with liraglutide plus behavioral therapy than with behavioral therapy alone.
Peptide
Liraglutide
Outcome
IncreaseFullness change at week 6
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 6 weeksAs given in this study (human).
Measurements
Fullness change at week 6
9.8 mm
IBT-liraglutide
Fullness change at week 6
−5.1 mm
IBT-alone
Source sentences
Summary
larger increases in fullness (-5.1 ± 3.2 vs +9.8 ± 3.0 mm, p = .001).
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695505
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity, the lower hunger with IBT-liraglutide than with IBT alone persisted at all assessments through week 24.
In plain wordsIn adults with obesity, lower hunger with liraglutide plus behavioral therapy lasted through week 24 compared with behavioral therapy alone.
Peptide
Liraglutide
Outcome
DecreaseHunger difference through week 24
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
These significant differences persisted at all assessments through week 24.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695506
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity, the lower food preoccupation with IBT-liraglutide than with IBT alone persisted at all assessments through week 24.
In plain wordsIn adults with obesity, less thinking about food with liraglutide plus behavioral therapy lasted through week 24 compared with behavioral therapy alone.
Peptide
Liraglutide
Outcome
DecreaseFood preoccupation difference through week 24
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
These significant differences persisted at all assessments through week 24.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695507
08HumanRandomized controlled trialEfficacy outcome
In adults with obesity, the greater fullness with IBT-liraglutide than with IBT alone persisted at all assessments through week 24.
In plain wordsIn adults with obesity, more fullness with liraglutide plus behavioral therapy lasted through week 24 compared with behavioral therapy alone.
Peptide
Liraglutide
Outcome
IncreaseFullness difference through week 24
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
These significant differences persisted at all assessments through week 24.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695508
09HumanRandomized controlled trialEfficacy outcome
In adults with obesity, meal liking did not differ between IBT alone and IBT with liraglutide.
In plain wordsIn adults with obesity, liking of meals did not differ between behavioral therapy alone and behavioral therapy with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeMeal liking
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3.0 mg/day · 52 weeksAs given in this study (human).
Source sentences
Summary
There were no differences between IBT-alone and IBT-liraglutide in meal liking.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
Report a problemFND-3092695509

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, the Multi-component regimen (IBT, liraglutide and a 12-week meal replacement diet) produced a loss of 12.1% of baseline weight at week 52, compared with 6.2% with IBT alone.
In plain wordsIn adults with obesity, a regimen of behavioral therapy, liraglutide and a meal replacement diet gave more weight loss than behavioral therapy alone.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at week 52 in Multi-component group
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss at week 52
12.1 % baseline weight
Multi-component
Weight loss at week 52
6.2 % baseline weight
IBT-alone
Source sentences
Summary
At week 52, participants treated by IBT-alone lost 6.2 ± 1.6% of baseline weight, compared with 11.8 ± 1.6% and 12.1 ± 1.5% in the IBT-liraglutide and Multi-component groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3092695502
11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, hunger at week 6 differed between the Multi-component regimen (IBT, liraglutide and meal replacement) and IBT alone.
In plain wordsIn adults with obesity, hunger at week 6 differed between a regimen with liraglutide and a meal replacement diet and behavioral therapy alone.
Peptide
Liraglutide
Outcome
Direction not reportedHunger at week 6, Multi-component versus IBT alone
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
IBT-alone and Multi-component participants differed in hunger at week 6
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3092695510
12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, food preoccupation differed at all assessments through week 24 between the Multi-component regimen and IBT alone.
In plain wordsIn adults with obesity, thinking about food differed through week 24 between a regimen with liraglutide and a meal replacement diet and behavioral therapy alone.
Peptide
Liraglutide
Outcome
Direction not reportedFood preoccupation through week 24, Multi-component versus IBT alone
Study
n: not reported in source
Comparator
IBT alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
and in food preoccupation at all assessments through week 24.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3092695511
13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, the Multi-component regimen reduced meal liking relative to IBT alone and to IBT-liraglutide, through weeks 40 and 52 respectively.
In plain wordsIn adults with obesity, a regimen with liraglutide and a meal replacement diet lowered liking of meals compared with the other two groups.
Peptide
Liraglutide
Outcome
DecreaseMeal liking, Multi-component group
Study
n: not reported in source
Comparator
IBT alone and IBT-liraglutide
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Multi-component participants reported reduced liking of meals relative to the IBT-alone and IBT-liraglutide groups through weeks 40 and 52, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined changes in appetite in a subsample of 113 adults with obesity (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) who participated in a 52-week trial.
Summary · context
Participants were randomized to intensive behavioral therapy alone (IBT-alone), IBT with liraglutide 3.0 mg/day (IBT-liraglutide), or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3092695512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT02911818

Lifestyle Modification and Liraglutide

University of Pennsylvanian = 150Sept 2016 to Dec 2018

Obesity

Trial page ClinicalTrials.govUpdated 7 May 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.